more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$51.17 USD

-2.38 (-4.44%)

Updated May 10, 2024 04:00 PM ET

After-Market: $51.35 +0.18 (0.35%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Selects Triple Combo Regimen for Regulatory Submission

by Zacks Equity Research Published on May 31,2019

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

biotechs

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on May 01,2019

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

biotechs

What's in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research Published on April 24,2019

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.

biotechs

Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag

by Zacks Equity Research Published on April 17,2019

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.

biotechs

Biotech ETFs Jump on Roche-Spark Deal

by Sweta Killa Published on February 26,2019

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

by Zacks Equity Research Published on February 26,2019

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.

biotechs

Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

by Zacks Equity Research Published on February 06,2019

Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

biotechs

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research Published on January 30,2019

On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

biotechs

Vertex Terminates COO Ian Smith on Code of Conduct Violation

by Zacks Equity Research Published on January 24,2019

Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.

pharmaceuticals

Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

by Zacks Equity Research Published on January 07,2019

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

biotechs

Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

by Zacks Equity Research Published on December 19,2018

Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

biotechs

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on November 30,2018

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.

CRSPNegative Net Change

CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research Published on November 12,2018

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.

CRSPNegative Net Change

Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research Published on November 09,2018

Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.

Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on November 08,2018

Is (CRSP) Outperforming Other Medical Stocks This Year?

CRSPNegative Net Change

CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 07,2018

CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CRSPNegative Net Change

Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on November 07,2018

Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.

biotechs

CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on November 07,2018

CRISPR THERAPTC (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRSPNegative Net Change

What's in the Cards for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research Published on November 06,2018

Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.

What Lies in Store for Ligand (LGND) This Earnings Season?

by Zacks Equity Research Published on November 06,2018

Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.